Bridge-helix cap: target and method for inhibition of bacterial RNA polymerase

US9060970B2 · kind B2 · utility

Assignee

• Rutgers, the State University of New Jersey · US

Inventors

• Richard H. Ebright · New Brunswick, US
• David Degen · New Brunswick, US
• Katherine Y. Ebright · New Brunswick, US

Key dates

• Filing date: Mar 19, 2012
• Grant date: Jun 23, 2015
• Expiry date: Mar 19, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance.